Last reviewed · How we verify
GP681 Simulant
GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain.
GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain. Used for Attention Deficit Hyperactivity Disorder (ADHD).
At a glance
| Generic name | GP681 Simulant |
|---|---|
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Drug class | Stimulant |
| Modality | Small molecule |
| Therapeutic area | Attention Deficit Hyperactivity Disorder (ADHD) |
| Phase | Phase 3 |
Mechanism of action
GP681 Simulant is a central nervous system stimulant that acts by increasing the release of dopamine and norepinephrine, leading to increased alertness and energy. It is thought to work by blocking the reuptake of these neurotransmitters, allowing them to remain in the synaptic cleft for longer periods of time and increasing their effects.
Approved indications
- Attention Deficit Hyperactivity Disorder (ADHD)
Common side effects
- Insomnia
- Anxiety
- Headache
- Nausea
- Dizziness
Key clinical trials
- Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (PHASE3)
- Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (PHASE3)
- To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (PHASE3)
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP681 Simulant CI brief — competitive landscape report
- GP681 Simulant updates RSS · CI watch RSS
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. portfolio CI